Clinical Trial Update: Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for poziotinib in stage IV lung adenocarcinoma with HER2 mutation (KASTT001) indicates the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Korean Association for the Study of Targeted Therapy | Conditions: HER2 Gene Mutation, Adenocarcinoma Lung Stage IV | Phase 2 | Status: COMPLETED